Of over 400 million people with diabetes, about one-third will develop diabetic kidney disease, a leading cause of end-stage renal disease that causes more than 950,000 deaths each year globally. These patients carry a significantly increased risk of cardiovascular morbidity and mortality. The link between renal disease and cardiovascular disease is poorly understood and this knowledge gap contributes to the suboptimal treatment options available for these patients. Improved understanding of the pathogenesis of diabetic kidney disease and its association on the development of cardiovascular disease is urgently needed to catalyze the development of novel therapeutics that can be targeted to the early stages of these diseases, before kidney and/or cardiovascular damage becomes irreversible. Currently approved therapeutics regimens can retard, but not prevent the progression of cardiovascular abnormalities and incidence of end-stage kidney disease. Moreover, these therapies are not cell specific, sometimes ineffective and are associated with side effects and intolerance.
There is a clear medical need for new therapeutic strategies to improve both kidney and cardiovascular function in diabetic patients.
In this Research Topic of Frontier in Pharmacology, we invite Original Research as well as Review articles to provide a deeper insight on the new pathophysiologic pathways and mechanisms to combat kidney fibrosis and cardiovascular complications. Although, there is still lack of suitable animal model to study diabetic kidney disease, we invite scientists to address this issue as well. We invite discussion on the mechanistic pathways that are profibrotic or antifibrotic in nature like the alteration in cytokine homeostasis, involvement of regulatory non-coding RNAs, metabolic alterations, changes in signaling mechanisms, upstream and downstream regulators of diabetic kidney disease. We will also include critical articles and Reviews studying the use of validated drugs in diabetes, new plant based and synthetic molecules in the treatment of diabetic kidney disease and cardiovascular dysfunctions.
The understanding of the critical pathways will guide the future therapies to combat the kidney fibrosis and cardiovascular complications in diabetes. We welcome the below themes but not limited to:
• Therapeutic regimens for the management of diabetes and diabetes kidney disease
• New therapeutic approaches for the management of cardiovascular functions
• Identification of pathological pathways, that contributes in diabetic nephropathy
• Cell and tissue specific mechanisms
• Regulatory microRNAs involved in the cardiovascular disorders and renal fibrosis
• Mechanisms of diabetic kidney disease
• Clinical data about cardiovascular functions and renal fibrosis in diabetic and non-diabetic patients
Of over 400 million people with diabetes, about one-third will develop diabetic kidney disease, a leading cause of end-stage renal disease that causes more than 950,000 deaths each year globally. These patients carry a significantly increased risk of cardiovascular morbidity and mortality. The link between renal disease and cardiovascular disease is poorly understood and this knowledge gap contributes to the suboptimal treatment options available for these patients. Improved understanding of the pathogenesis of diabetic kidney disease and its association on the development of cardiovascular disease is urgently needed to catalyze the development of novel therapeutics that can be targeted to the early stages of these diseases, before kidney and/or cardiovascular damage becomes irreversible. Currently approved therapeutics regimens can retard, but not prevent the progression of cardiovascular abnormalities and incidence of end-stage kidney disease. Moreover, these therapies are not cell specific, sometimes ineffective and are associated with side effects and intolerance.
There is a clear medical need for new therapeutic strategies to improve both kidney and cardiovascular function in diabetic patients.
In this Research Topic of Frontier in Pharmacology, we invite Original Research as well as Review articles to provide a deeper insight on the new pathophysiologic pathways and mechanisms to combat kidney fibrosis and cardiovascular complications. Although, there is still lack of suitable animal model to study diabetic kidney disease, we invite scientists to address this issue as well. We invite discussion on the mechanistic pathways that are profibrotic or antifibrotic in nature like the alteration in cytokine homeostasis, involvement of regulatory non-coding RNAs, metabolic alterations, changes in signaling mechanisms, upstream and downstream regulators of diabetic kidney disease. We will also include critical articles and Reviews studying the use of validated drugs in diabetes, new plant based and synthetic molecules in the treatment of diabetic kidney disease and cardiovascular dysfunctions.
The understanding of the critical pathways will guide the future therapies to combat the kidney fibrosis and cardiovascular complications in diabetes. We welcome the below themes but not limited to:
• Therapeutic regimens for the management of diabetes and diabetes kidney disease
• New therapeutic approaches for the management of cardiovascular functions
• Identification of pathological pathways, that contributes in diabetic nephropathy
• Cell and tissue specific mechanisms
• Regulatory microRNAs involved in the cardiovascular disorders and renal fibrosis
• Mechanisms of diabetic kidney disease
• Clinical data about cardiovascular functions and renal fibrosis in diabetic and non-diabetic patients
